Grace Therapeutics, Inc. Sustainability Profile
Grace Therapeutics, Inc., a pioneering biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for neurological disorders. Founded in 2015, the company has made significant strides in advancing its proprietary drug delivery systems, particularly in the treatment of conditions such as epilepsy and other central nervous system disorders. With a commitment to enhancing patient outcomes, Grace Therapeutics offers unique formulations that improve the bioavailability and efficacy of existing medications. Their cutting-edge approach has positioned them as a leader in the biopharmaceutical industry, garnering recognition for their contributions to drug development. As they continue to expand their operational reach, Grace Therapeutics remains dedicated to transforming the landscape of neurological treatment through science and innovation.
DitchCarbon Score
How does Grace Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Grace Therapeutics, Inc.'s score of 23 is lower than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Grace Therapeutics, Inc.'s reported carbon emissions
Grace Therapeutics, Inc., headquartered in the US, currently does not have any reported carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. As a result, Grace Therapeutics has not established any significant climate commitments or initiatives aimed at reducing its carbon footprint. Without emissions data or reduction strategies, it is challenging to assess the company's environmental impact or its alignment with industry standards for climate action. In the context of the broader industry, many companies are increasingly adopting science-based targets and sustainability initiatives to mitigate climate change. However, Grace Therapeutics has yet to publicly commit to such measures or report on its emissions, leaving a gap in its climate accountability.
How Carbon Intensive is Grace Therapeutics, Inc.'s Industry?
How Carbon Intensive is Grace Therapeutics, Inc.'s Location?
Grace Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Grace Therapeutics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
